Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Taiyo Can No Longer Be Family-Owned Company: President Aratani
April 19, 2010
- AnGes MG to Codevelop NF-κB Decoy with Shionogi
April 19, 2010
- Ajinomoto Pharm. to Enter Southeast Asian Market
April 19, 2010
- DB on Medicinal Plants Posted on NIBIO Website
April 19, 2010
- HPs Have Stronger Resistance to Generics than GPs
April 19, 2010
- Valsartan Delays Progression to Type 2 Diabetes in CV Patients with IGT
April 19, 2010
- Daiichi Sankyo Aims at 2nd Place in ARB Market in FY2012
April 19, 2010
- Korosho to Prepare New GLs for BE Testing for Generics
April 19, 2010
- Sutent Extends OS in Japanese mRCC Patients in PII
April 19, 2010
- Mochida to Boost Sales to ¥89.0 Bil. in FY2012
April 19, 2010
- Dispensing Pharmacies' Total Sales Will Continue to Decrease: JPA's Mr Iwatsuki
April 19, 2010
- Avastin + Standard Chemotherapy Significantly Extend PFS in NSCLC
April 19, 2010
- Hisamitsu: Profits Down Following Acquisition of Noven Pharma
April 19, 2010
- Daiichi Sankyo Applies for Edoxaban in Japan
April 19, 2010
- Erbitux + Irinotecan Effective for KRAS Wild-Type CRC
April 19, 2010
- Kyowa Kirin Ranked No. 5 in Development of Antibody Drugs: CEO Matsuda
April 19, 2010
- Medway Data Falsification Was Organized: Committee Report
April 19, 2010
- 48% Fewer Deaths with Ticagrelor than Clopidogrel
April 19, 2010
- Victoza's NHI Pricing Withheld
April 12, 2010
- Dr Haranaka Elected as New JMA President
April 12, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…